Form 4: Foghorn Therapeutics Officer Granted Stock Options

Steven F. Bellon, Chief Scientific Officer of Foghorn Therapeutics, was granted stock options for 140,000 shares of common stock.

Summary

• Steven F. Bellon, the Chief Scientific Officer of Foghorn Therapeutics Inc. (FHTX), was granted stock options.
• The transaction occurred on January 22, 2025.
• Bellon received options to purchase 140,000 shares of common stock at an exercise price of $4.37 per share.
• The options vest as to 25% of the underlying shares on January 22, 2026, and then at a rate of 6.25% per quarter thereafter.
• Following the transaction, Bellon directly owns options for 140,000 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies.
• The vesting schedule of 25% after one year followed by quarterly vesting is a standard practice.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The stock option grant incentivizes the Chief Scientific Officer to contribute to the company's success, potentially benefiting shareholders.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal.

Key Dates